アレルアグノスティック変異KRAS阻害剤は,腫瘍維持信号を抑制し,臓がんにおける腫瘍免疫を再プログラムする.
PubMedで要約を見る
まとめ
この要約は機械生成です。新しい変異KRAS阻害剤 (panKRASi) は,臨床前モデルにおいて,臓がんの増殖を効果的に抑制した. 抗腫瘍免疫も強化しましたが,YAPシグナル伝達と免疫チェックポイントのアップレギュレーションによって抵抗が生じました.
科学分野
- 腫瘍学
- 分子生物学
- 免疫学
背景
- KRAS変異は がんでは一般的ですが 標的を絞ることは困難です
- 小分子阻害剤は,突然変異したKRASを直接標的とする新しいアプローチを提供します.
- 管腺がん (PDAC) は,KRAS変異が頻繁に見られるがんである.
研究 の 目的
- 管腺癌 (PDAC) の治療における新しい汎RAS阻害剤 (panKRASi) のBI-2493の臨床前有効性を評価する.
- panKRASiの効能と耐性の基礎にある分子メカニズムの調査.
- 抵抗を克服し,治療結果を高めるための組み合わせ戦略を探求する.
主な方法
- 様々なPDACモデル (細胞系,PDX,シンジェニック・オートトープ,遺伝子組み換えマウスモデル) の臨床前評価.
- 経路阻害と免疫変化を評価するためのトランスクリプトミック,プロテオミック,およびフォスフォプロテオミックプロファイリング.
- 腫瘍の微小環境 (TME) と免疫細胞の浸透の分析
- YAPシグナル伝達と免疫チェックポイントを含む抵抗メカニズムの調査
主要な成果
- BI-2493は,様々な臨床前モデルにおいて,著しい腫瘍増殖抑制と生存延長を示した.
- RAS経路の阻害が確認され,LKB1/AMPKの目標値が上昇した.
- panKRASi治療は腫瘍内CD8+T細胞を増加させ,TMEを再構成し,免疫チェックポイントの阻害に敏感にします.
- panKRASi単独治療に対する耐性は,YAPシグナル伝達と免疫チェックポイント発現の増加と関連していた.
結論
- BI-2493は,RAS経路を阻害し,免疫応答を調節することによって,PDACに対する有望な臨床前有効性を示しています.
- YAPの活性化や免疫回避などの耐性メカニズムを理解することは,持続的な治療に不可欠です.
- PDACで持続的な反応を達成するために,panKRASiを含む組み合わせ戦略が必要になる可能性があります.
関連する概念動画
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

